Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Apr
16
Today In Oncology
Is Standard of Care Optimal for the Individual Patient?
LuPSMA-617 and Pembrolizumab in mCRPC
ASH-ISTH Create Guidelines for Pediatric VTE Prophylaxis
Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers
New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo